Original Publication Date: 12 March, 2014
Publication / Source: Future Oncology
Authors: Nicholas G Zaorsky, Kosj Yamoah, Madhukar L Thakur, Edouard J Trabulsi, Timothy N Showalter, Mark D Hurwitz, Adam P Dicker & Robert B Den
Approximately a third of men with localized prostate cancer who are treated with external beam radiation therapy (EBRT) or radical prostatectomy (RP) develop biochemical failure (BF). Presumably, BF will progress to distant metastasis and prostate cancer-specific mortality in some patients over subsequent years. Accurate detection of recurrent disease is important because it allows for appropriate treatment selection (e.g., local vs systemic therapy) and early delivery of therapy (e.g., salvage EBRT), which affect patient outcome.